GCLC

Across TCGA pan-cancer cohorts, GCLC RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of GCLC’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where GCLC RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GCLC is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

KIRP, LUAD, and LUSC are the cancer types where GCLC tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GCLC RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	II,III,IV	+1.078	<.001	9	view →
LUAD	Male	II,III,IV	+2.629	<.001	8	view →
LUSC	Male	II,III,IV	+2.513	<.001	8	view →
HNSC	Male	III,IV	+1.614	<.001	8	view →
THCA	Male	III,IV	−0.885	<.001	8	view →
KIRC	All	All	+0.359	<.001	8	view →
COAD	Male	II,III,IV	+0.471	<.001	6	view →
STAD	Male	II,III,IV	+0.589	.012	3	view →
BRCA	All	All	−0.153	.042	2	view →
CHOL	Female	All	−1.323	.030	1	view →
LIHC	Male	All	+0.400	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

GCLC–KIRP

Open the KIRP breakdown →